The skin autofluorescence may help to select patients with Type 2 diabetes candidates for screening to revascularization procedures
Abstract Chen et al. recently related the skin autofluorescence (SAF) of Advanced Glycation End-products to subclinical cardiovascular disease in the 3001 participants from the general population (Rotterdam study), with a particularly close relationship for the 413 subjects with diabetes. Because conventional vascular risk factors do not capture the risk in diabetes very well, this relationship may help to select high-risk individuals for the screening of silent myocardial ischemia, which has yet to prove its benefit in randomized controlled trials. Among 477 patients with uncontrolled and/or complicated Type 2 Diabetes, we measured the SAF ten years ago, and we registered new revascularizations during a 54-months follow-up. The patients with SAF > 2.6 Arbitrary units (AUs), the median population value, experienced more revascularizations of the coronary (17/24) and lower-limb arteries (13/17) than patients with a lower SAF, adjusted for age, sex, diabetes duration, vascular complications, and smoking habits: HR 2.17 (95% CI: 1.05–4.48), p = 0.035. The SAF has already been reported to predict cardiovascular events in three cohorts of people with diabetes. We suggest that its measurement may help to improve the performance of the screening before vascular explorations and revascularizations..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Cardiovascular diabetology - 23(2024), 1 vom: 13. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alkhami, Fadi [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Advanced glycation end-products |
|---|
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s12933-024-02121-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054384478 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054384478 | ||
| 003 | DE-627 | ||
| 005 | 20240114064626.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12933-024-02121-5 |2 doi | |
| 035 | |a (DE-627)SPR054384478 | ||
| 035 | |a (SPR)s12933-024-02121-5-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alkhami, Fadi |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The skin autofluorescence may help to select patients with Type 2 diabetes candidates for screening to revascularization procedures |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Abstract Chen et al. recently related the skin autofluorescence (SAF) of Advanced Glycation End-products to subclinical cardiovascular disease in the 3001 participants from the general population (Rotterdam study), with a particularly close relationship for the 413 subjects with diabetes. Because conventional vascular risk factors do not capture the risk in diabetes very well, this relationship may help to select high-risk individuals for the screening of silent myocardial ischemia, which has yet to prove its benefit in randomized controlled trials. Among 477 patients with uncontrolled and/or complicated Type 2 Diabetes, we measured the SAF ten years ago, and we registered new revascularizations during a 54-months follow-up. The patients with SAF > 2.6 Arbitrary units (AUs), the median population value, experienced more revascularizations of the coronary (17/24) and lower-limb arteries (13/17) than patients with a lower SAF, adjusted for age, sex, diabetes duration, vascular complications, and smoking habits: HR 2.17 (95% CI: 1.05–4.48), p = 0.035. The SAF has already been reported to predict cardiovascular events in three cohorts of people with diabetes. We suggest that its measurement may help to improve the performance of the screening before vascular explorations and revascularizations. | ||
| 650 | 4 | |a Advanced glycation end-products |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Skin autofluorescence |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Type 2 diabetes |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Revascularization |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Borderie, Gauthier |4 aut | |
| 700 | 1 | |a Foussard, Ninon |4 aut | |
| 700 | 1 | |a Larroumet, Alice |4 aut | |
| 700 | 1 | |a Blanco, Laurence |4 aut | |
| 700 | 1 | |a Barbet-Massin, Marie-Amélie |4 aut | |
| 700 | 1 | |a Ferriere, Amandine |4 aut | |
| 700 | 1 | |a Ducos, Claire |4 aut | |
| 700 | 1 | |a Mohammedi, Kamel |4 aut | |
| 700 | 1 | |a Fawaz, Sami |4 aut | |
| 700 | 1 | |a Couffinhal, Thierry |4 aut | |
| 700 | 1 | |a Rigalleau, Vincent |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiovascular diabetology |d London : BioMed Central, 2002 |g 23(2024), 1 vom: 13. Jan. |w (DE-627)SPR028533577 |w (DE-600)2093769-6 |x 1475-2840 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2024 |g number:1 |g day:13 |g month:01 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12933-024-02121-5 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2024 |e 1 |b 13 |c 01 | ||